-$0.74 EPS Expected for Juno Therapeutics, Inc. (JUNO) This Quarter
Brokerages expect Juno Therapeutics, Inc. (NASDAQ:JUNO) to post earnings of ($0.74) per share for the current quarter, Zacks reports. Six analysts have provided estimates for Juno Therapeutics’ earnings. The highest EPS estimate is ($0.68) and the lowest is ($0.79). Juno Therapeutics reported earnings per share of ($0.65) in the same quarter last year, which indicates a negative year over year growth rate of 13.8%. The firm is scheduled to issue its next quarterly earnings results on Thursday, August 3rd.
On average, analysts expect that Juno Therapeutics will report full year earnings of ($3.00) per share for the current financial year, with EPS estimates ranging from ($3.14) to ($2.77). For the next fiscal year, analysts forecast that the business will post earnings of ($3.78) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Juno Therapeutics.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by $0.01. Juno Therapeutics had a negative return on equity of 24.57% and a negative net margin of 288.66%. The firm had revenue of $19.30 million during the quarter, compared to analysts’ expectations of $16 million. During the same period in the previous year, the company posted ($0.78) earnings per share. The company’s quarterly revenue was up 96.9% compared to the same quarter last year.
A number of research analysts recently issued reports on JUNO shares. Cowen and Company reiterated a “buy” rating and set a $36.00 price objective (down from $41.00) on shares of Juno Therapeutics in a research note on Thursday, March 30th. Vetr upgraded Juno Therapeutics from a “buy” rating to a “strong-buy” rating and set a $25.42 price objective for the company in a research note on Tuesday, March 21st. Leerink Swann reiterated an “outperform” rating on shares of Juno Therapeutics in a research note on Monday, June 12th. Citigroup Inc. cut their price objective on Juno Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, April 4th. Finally, Zacks Investment Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a research note on Tuesday, July 11th. One analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the stock. Juno Therapeutics currently has an average rating of “Buy” and a consensus price target of $30.81.
In related news, CFO Steve Harr sold 8,750 shares of the stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $30.00, for a total transaction of $262,500.00. Following the sale, the chief financial officer now owns 736,189 shares in the company, valued at approximately $22,085,670. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Anthony B. Evnin purchased 9,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The shares were bought at an average price of $24.40 per share, for a total transaction of $219,600.00. Following the acquisition, the director now directly owns 66,301 shares in the company, valued at approximately $1,617,744.40. The disclosure for this purchase can be found here. Insiders have sold a total of 41,500 shares of company stock worth $1,230,360 over the last ninety days. Insiders own 15.26% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in JUNO. Baillie Gifford & Co. raised its stake in Juno Therapeutics by 1.2% in the first quarter. Baillie Gifford & Co. now owns 11,197,863 shares of the biopharmaceutical company’s stock valued at $248,481,000 after buying an additional 135,908 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Juno Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 6,153,812 shares of the biopharmaceutical company’s stock valued at $136,553,000 after buying an additional 303,912 shares during the period. BlackRock Inc. increased its position in shares of Juno Therapeutics by 31,399.7% in the first quarter. BlackRock Inc. now owns 4,183,793 shares of the biopharmaceutical company’s stock valued at $92,838,000 after buying an additional 4,170,511 shares during the period. BB Biotech AG increased its position in shares of Juno Therapeutics by 16.8% in the first quarter. BB Biotech AG now owns 2,185,000 shares of the biopharmaceutical company’s stock valued at $48,485,000 after buying an additional 315,000 shares during the period. Finally, First Trust Advisors LP increased its position in shares of Juno Therapeutics by 47.1% in the first quarter. First Trust Advisors LP now owns 1,377,667 shares of the biopharmaceutical company’s stock valued at $30,570,000 after buying an additional 440,984 shares during the period. Institutional investors own 64.51% of the company’s stock.
Shares of Juno Therapeutics (NASDAQ JUNO) traded up 1.76% during midday trading on Monday, hitting $27.74. 564,903 shares of the stock were exchanged. Juno Therapeutics has a 52-week low of $17.52 and a 52-week high of $35.04. The firm’s 50 day moving average price is $24.94 and its 200-day moving average price is $22.57. The stock’s market cap is $2.89 billion.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.